Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

This news follows a recent Phase 3 trial where Keytruda®, another immunotherapy, failed to show similar benefits in the same setting. The success of Libtayo in this trial could represent a ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

This news follows a recent Phase 3 trial where Keytruda®, another immunotherapy, failed to show similar benefits in the same setting. The success of Libtayo in this trial could represent a significant ...

Several factors, including histopathologic subtypes of liver metastases, tumor-infiltrating lymphocyte (TIL) enrichment, and molecular subtypes, may help guide the identification of candidates for ...

Umoja Biopharma announced a $100 million Series C round that will help the Seattle-based company further develop its CAR T-cell immunotherapy treatments for cancer. Umoja is developing a multi ...

Get Instant Summarized Text (Gist) A phase 1 clinical trial indicates that a new off-the-shelf immunotherapy using CAR-NK cells shows promise for treating B-cell lymphomas. This approach, derived ...